Skip to content
Let’s Talk(678) 203-0800 Partner ProgramDocumentationDocsBlogContact
Industries · Pharma & Life Sciences

The integration platform that doesn’t cost you a 483.

Regulated life-sciences integrations have to survive an audit on no notice. 21 CFR Part 11 e-signature lineage, DSCSA serialization, CDISC SDTM/ADaM clinical data, GxP validated environments, and HL7 v2 site integrations - all with the prior-state preservation and chain-of-custody FDA, EMA, and PMDA expect.

LIMSLabWare MESbatch record QMSVeeva SERIALIZATIONDSCSA Art2link
Our Clients
The realities

What integration looks like inside a regulated life-sciences estate.

Reality 01
Every change has consequences

A config tweak is a regulated change-control event - requested, approved, executed, witnessed, and archived. The integration platform owns half that surface.

Reality 02
Validation cycles are 9 months

IQ, OQ, PQ for every system touching GxP data. The integration layer can’t hide behind "infrastructure" - auditors check it specifically.

Reality 03
Serialization is non-negotiable

DSCSA, EU FMD, Russia CRPT - each unit-level serial flows through manufacturing, packaging, distribution, and dispensing with bidirectional verification at every hand-off.

Reality 04
Clinical + commercial don’t mix

CDISC SDTM/ADaM in the clinical zone, SAP / HL7 / EDI in commercial. The two estates coexist with separation enforced through identity, network, and audit boundaries.

Where it runs

Every GxP system, one backbone.

From the fill-finish line to the QC lab - the same runtime, the same validated audit trail.

Pharmaceutical production cleanroom
Manufacturing

Drug product & fill-finish

DSCSA and EU FMD serialization across production sites.

Life-sciences laboratory
Labs

R&D & QC laboratories

LIMS, ELN, and instruments integrated under GxP validation.

Pharmaceutical serialization packaging line
Packaging

Serialization & packaging

Aggregation and reporting for global track-and-trace.

21 CFR Part 11 · audit demonstrator

A regulated change, with its full chain of custody.

A representative batch-release decision moving through Art2link, as the operator sees it in the audit ledger. Every action carries its prior state, reason, e-signature, and a tamper-evident hash. The document an FDA inspector asks for - produced on demand.

Audit ledger · Batch LOT-2026-D8841 · Active pharmaceutical ingredient
Batch release · GxP-validated change
01Entry
QC review completed 2026-05-12 · 09:14:32 UTC · system Art2link · LIMS bridge
Action Routine QC test panel completed for batch LOT-2026-D8841. All 14 results imported from LabWare LIMS via HL7 v2.5.1 OUL^R22 message.
Prior state Status: AWAITING_QC · 0 of 14 results
New state Status: QC_COMPLETE · 14 of 14 results · all in spec
Performed byLabWare system → LIMS bridge
E-signatureN/A — system event
Record hashsha256:7a4f…b2c9
02Entry
QC manager approves batch for release 2026-05-12 · 11:48:07 UTC · system Art2link · QMS interface
Reason for change Batch meets all release criteria per SOP-QC-2412 v3.1. Test panel within acceptance limits, no deviations open.
Prior state Status: QC_COMPLETE · disposition: PENDING
New state Status: QC_APPROVED · disposition: PROVISIONAL_RELEASE
Performed byMaria Chen · QC Manager · empId QC-441
E-signaturePIN + 2FA · TOTP verified
Record hashsha256:e02d…91af · chain:OK
03Entry
Qualified Person releases batch for commerce 2026-05-12 · 14:22:51 UTC · system Art2link · ERP-MES bridge
Reason for change Final disposition by Qualified Person per EU GMP Annex 16 and 21 CFR Part 211. Batch records reviewed: master record (MBR-2412), executed record (EBR-D8841), QC test panel, raw material lot certificates. Batch fit for market.
Prior state Status: QC_APPROVED · disposition: PROVISIONAL_RELEASE
New state Status: RELEASED · disposition: COMMERCIAL · DSCSA serials activated
Performed byDr. Anders Sørensen · QP · empId QP-007
E-signaturePIN + 2FA + biometric · WebAuthn
Record hashsha256:c1be…334d · chain:OK
04Entry
Downstream system propagation 2026-05-12 · 14:23:04 UTC · system Art2link · propagation pipeline
Action Release decision propagated to downstream systems: SAP S/4HANA finance & inventory (IDoc DELVRY07), warehouse (HighJump WMS), DSCSA repository (EPCIS 1.2 event), TraceLink network for trading-partner verification.
Systems updated SAP: pending · WMS: pending · DSCSA: pending
New state SAP · WMS · DSCSA · TraceLink — all confirmed
Performed byArt2link propagation pipeline · automated
E-signatureSystem signature · derived from entry 03
Record hashsha256:f0a7…68bb · chain:OK
Every entry is immutable. Records are written to append-only storage with per-entry SHA-256 hashing. Each entry hashes its own contents plus the previous entry’s hash, forming an integrity chain that detects tampering. The ledger exports to FDA-compliant PDF on request, and inspectors can be granted read-only access without exposing the underlying systems.
Clinical & commercial stack

The regulated and commercial systems an L/S estate runs.

Manufacturing & QC · GxP

  • SAP ME / DMC regulated MES
  • Rockwell PharmaSuite
  • Werum PAS-X regulated MES
  • LabWare LIMS
  • STARLIMS
  • OSIsoft PI historian

Clinical & trials · CDISC

  • Veeva Vault Clinical
  • Medidata Rave EDC
  • Oracle Clinical / RDC
  • Argus Safety
  • SAS Clinical
  • CDISC SDTM/ADaM datasets

Supply chain & serialization · DSCSA · FMD

  • SAP S/4HANA · ATTP serialization
  • TraceLink network
  • rfxcel · Antares Vision
  • EPCIS 1.2 events
  • EU Hub · NMVS verification
  • GS1 GTIN / SSCC labels
Compliance posture

The regulatory surface an integration platform owns.

Art2link runs in your Azure subscription - clinical, GxP, and PHI data never leave your tenant. GxP-validated deployment topology with IQ/OQ/PQ scripts. Audit retention configurable to FDA 21 CFR Part 211 (10+ years). EU GMP Annex 11 controls supported. Inspector read-only audit access on request.

21 CFR Part 11E-signature + audit
EU GMP Annex 11Computerized systems
DSCSAPharma serialization
EU FMDFalsified medicines
Tenant-scopedRuns in your Azure
SOC 2 Type 1In progress
GxP compliance review

Walk a real regulated flow with our team.

30 minutes with a senior architect who has shipped in regulated pharma. Bring a compliance question - DSCSA, Part 11, validation strategy - or a flow to walk; leave with a tailored reference architecture.